$APGE
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Michael Thomas Henderson
CEO
196
Employees
$134.28
Current Price
$3.85B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 10 | $19,174,131.66 | 151,900 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 13 | $21,248,747.39 | 177,400 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 20,000 | $133.63 | $2,672,600.00 | View Details |
| Jul 1, 2026 | Dambkowski Carl Chief Medical Officer | Sale | 5,500 | $132.74 | $730,070.00 | View Details |
| Jun 22, 2026 | Dambkowski Carl Chief Medical Officer | Sale | 26,400 | $132.60 | $3,500,640.00 | View Details |
| Jun 22, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 80,000 | $132.54 | $10,603,200.00 | View Details |
| Jun 10, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 1,080 | $84.18 | $90,914.40 | View Details |
| Jun 10, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 2,305 | $86.27 | $198,852.35 | View Details |
| Jun 10, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 7,654 | $82.78 | $633,598.12 | View Details |
| Jun 10, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 1,577 | $85.19 | $134,344.63 | View Details |
| Jun 10, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 6,770 | $82.21 | $556,561.70 | View Details |
| Jun 10, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 614 | $86.89 | $53,350.46 | View Details |
| Jun 3, 2026 | Dambkowski Carl Chief Medical Officer | Sale | 5,500 | $78.71 | $432,905.00 | View Details |
| May 13, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 18,659 | $82.05 | $1,530,970.95 | View Details |
| May 13, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 1,341 | $82.58 | $110,739.78 | View Details |
71 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history